Although there are currently no commercial inhibitors of IGF2BP2, a few reports recently identified some small-molecule IGF2BP2 inhibitors in colorectal cancer [45] and T-cell acute lymphoblastic leukemia [46]. Here, IGF2BP2 is linked to T-cell acute lymphoblastic leukemia.